Glycosylated haemoglobin as a predictor of cardiovascular events and mortality: a protocol for a systematic review and meta-analysis.
Glycosylated haemoglobin as a predictor of cardiovascular events and mortality: a protocol for a systematic review and meta-analysis.
复制标题
DOI：
10.1136/bmjopen-2016-012229
复制
发表时间：
2016-07-11
期刊：
影响因子：
2.9
通讯作者：
Martínez-Vizcaíno V
中科院分区：
文献类型：
--
作者：
Cavero-Redondo I;Peleteiro B;Álvarez-Bueno C;Rodríguez-Artalejo F;Martínez-Vizcaíno V
糖化血红蛋白水平（HbA 1c）是过去2-3个月内平均血糖浓度的指标，在临床实践中用作方便和众所周知的生物标志物。 目前流行病学证据表明，HbA 1c水平是心肌梗死、脑卒中、冠心病和心力衰竭等心血管事件的独立危险因素。本方案旨在进行系统性综述和荟萃分析，以确定HbA 1c水平与心血管结局和死亡原因的关系，并基于已发表的观察性研究数据分析作为心血管疾病和/或死亡率预测因子的HbA 1c水平范围。将使用Medline、EMBASE、科克伦对照试验中心注册库、科克伦系统评价数据库和Web of Science数据库进行检索。将纳入以葡萄牙语、西班牙语或英语撰写的观察性研究。预后研究质量工具将用于评估系统综述或荟萃分析中纳入的研究的偏倚风险。心血管结局和死亡原因的HR及其95% CI将被确定为主要结局。将根据心血管结局、研究的死亡原因和研究纳入的人群类型进行亚组分析。本系统性综述将综合使用HbA 1c水平作为心血管疾病结局和/或死亡率的预后标志物的可能性的证据。研究结果将在同行评审的期刊上发表。不需要伦理批准，因为用于本系统性综述的数据将从已发表的研究中获得，并且不会涉及隐私问题。PROSPERO CRD 42015032552。
Glycosylated haemoglobin level (HbA1c) is an indicator of the average blood glucose concentrations over the preceding 2–3 months and is used as a convenient and well-known biomarker in clinical practice. Currently, epidemiological evidence suggests that HbA1c level is an independent risk factor for cardiovascular events such as myocardial infarction, stroke, coronary heart disease and heart failure. This protocol aim is to conduct a systematic review and meta-analysis to determine relationships of HbA1c levels with cardiovascular outcomes and cause of death, and to analyse the range of HbA1c levels that is a predictor of cardiovascular disease and/or mortality based on data from published observational studies. The search will be conducted using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science databases from their inception. Observational studies written in Portuguese, Spanish or English will be included. The Quality In Prognosis Studies tool will be used to assess the risk of bias for the studies included in the systematic review or meta-analysis. HRs for cardiovascular outcomes and causes of death with 95% CIs will be determined as primary outcomes. Subgroup analyses will be performed based on cardiovascular outcomes, cause of death studied, and type of population included in the studies. This systematic review will synthesise evidence on the potential of using HbA1c level as a prognostic marker for cardiovascular disease outcomes and/or mortality. The results will be disseminated by publication in a peer-reviewed journal. Ethics approval will not be needed because the data used for this systematic review will be obtained from published studies and there will be no concerns about privacy. PROSPERO CRD42015032552.